116 related articles for article (PubMed ID: 9223386)
21. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Illingworth DR; Erkelens DW; Keller U; Thompson GR; Tikkanen MJ
Lancet; 1994 Jun; 343(8912):1554-5. PubMed ID: 7911877
[No Abstract] [Full Text] [Related]
22. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hyperlipidemia in cardiac transplant recipients.
Bilchick KC; Henrikson CA; Skojec D; Kasper EK; Blumenthal RS
Am Heart J; 2004 Aug; 148(2):200-10. PubMed ID: 15308989
[TBL] [Abstract][Full Text] [Related]
24. Combination statin-fibrate therapy: safety aspects.
Franssen R; Vergeer M; Stroes ES; Kastelein JJ
Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
[TBL] [Abstract][Full Text] [Related]
25. [Diabetes mellitus and hyperlipidemia].
Toyota T
Nihon Naika Gakkai Zasshi; 1992 Nov; 81(11):1737-8. PubMed ID: 1479211
[No Abstract] [Full Text] [Related]
26. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Haffner SM; Ashraf T
Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
[TBL] [Abstract][Full Text] [Related]
27. [Micronized fenofibrate and LDL-cholesterol subfractions].
Soska V
Vnitr Lek; 1999 Jul; 45(7):441-3. PubMed ID: 11045166
[TBL] [Abstract][Full Text] [Related]
28. Management of hyperlipidemia in diabetes.
Vinik AI; O'Brian JT; Georges LP; Leichter SB; Janin Y
Compr Ther; 1995 Oct; 21(10):602-9. PubMed ID: 8565431
[No Abstract] [Full Text] [Related]
29. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Skrha J; Stulc T; Hilgertová J; Weiserová H; Kvasnicka J; Ceska R
Eur J Pharmacol; 2004 Jun; 493(1-3):183-9. PubMed ID: 15189781
[TBL] [Abstract][Full Text] [Related]
30. The role of fibrates in a statin world.
Bloomfield HE
Arch Intern Med; 2006 Apr; 166(7):715-6. PubMed ID: 16606806
[No Abstract] [Full Text] [Related]
31. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Janka HU; Standl A; Holler HD; Mehnert H
MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
[No Abstract] [Full Text] [Related]
32. [Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534006
[No Abstract] [Full Text] [Related]
33. Statin-induced myositis migrans.
Sinzinger H
Wien Klin Wochenschr; 2002 Nov; 114(21-22):943-4. PubMed ID: 12528328
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
35. Three new drugs for hyperlipidemia.
Conn Med; 2003 May; 67(5):279-81. PubMed ID: 12802842
[No Abstract] [Full Text] [Related]
36. In vivo model for dyslipidemia with diabetes mellitus in hamster.
Bhatia G; Rizvi F; Saxena R; Puri A; Khanna AK; Chander R; Wulff EM; Rastogi AK
Indian J Exp Biol; 2003 Dec; 41(12):1456-9. PubMed ID: 15320502
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
38. Management of dyslipidemia in adults with diabetes.
American Diabetes Association
Diabetes Care; 2000 Jan; 23 Suppl 1():S57-60. PubMed ID: 12017680
[No Abstract] [Full Text] [Related]
39. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
40. Fenofibrate-induced myopathy.
Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
